Phase II trial of capecitabine and vinorelbine as first-line chemotherapy for metastatic breast cancer patients

Anticancer Research

Volumn 26, Issue 3 B, 2006, Pages 2451-2456

  Ghosn, Marwan ^a   Kattan, Joseph ^a   Farhat, Fadi ^b   Younes, Fariha ^a   Gasmi, Jamal ^c  

^a SAINT JOSEPH UNIVERSITY   (Lebanon)

^b Hammoud University Hospital Medical Center   (Lebanon)

^c Centre d'Immunologie Pierre Fabre   (France)

Author keywords

Breast cancer; Capecitabine; Metastatic breast cancer; Navcap; Vinorelbine

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CYTOTOXIC AGENT; FLUOROURACIL; NAVELBINE; TAXANE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; METASTASIS; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; VINBLASTINE;

EID: 33745577655     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Perez EA: Current management of metastatic breast cancer. Semin Oncol 26: 1-10, 1999.
2. Bernard-Marty C, Cardoso F and Piccart MJ: Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist P: 617-632, 2004.
3. Fumoleau P, Delgado FM, Delozier T et al: Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 11: 1245-1252, 1993.
4. Berruti A, Sperone P, Bottini A et al: Phase II study of protracted fluorouracil infusion as second or third-line approach for advanced breast cancer patients previously treated with anthracycline. J Clin Oncol 18: 3370-3377, 2000.
5. Aboul Enein M, Moussa M, Sabri A et al: Vinorelbine-5 fluorouracil combination as first line chemotherapy in anthracycline pretreated patients with metastatic breast cancer. Ann Oncol 15(S3): 47 (Abstr 177P), 2004.
6. Nole F, De Braud F, Aapro M et al: Phase I-II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer: a regimen with a low subjective toxic burden. Ann Oncol 8: 865-870, 1997.
7. Dieras V, Extra J M, Bellissant E et al: Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method. J Clin Oncol 14: 3097-3104, 1996.
8. Blum JL, Jones SE, Buzdar AU et al: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17: 485-494, 1999.
9. Blum JL, Dieras V, Lorusso PM et al: Multicenter phase II study of oral capecitabine in taxane-pretreated metastatic breast cancer. Cancer 92: 1759-1768, 2001.
10. O'Shaughnessy J, Blum J, Moiseyenko V et al: Randomised open-label, phase II trial of oral capecitabine (xeloda) versus a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 12: 1247-1254, 2001.
11. O'Shaughnessy J, Miles D, Vukelja S et al: Superior survival, with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20: 2812-2823, 2002.
12. Sawada N, Fujimoto-Ouchi F, Ishikawa T et al: Antitumor activity of combination therapy with capecitabine plus vinorelbine, and capecitabine plus gemcitabine in human tumor xenograft models. Proc Am Assoc Cancer Res 43: 1088 (Abstr 5388), 2002.
13. Hess D, Thurlimann B, Pagani O et al: Capecitabine and vinorelbine in elderly patients (≥65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99). Ann Oncol 75: 1760-1765, 2004.
14. Ahn JH, Kim SB, Kim SM et al: Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane. J Korean Med Sci 19: 547-553, 2004.
15. Welt A, Von Minckwitz G, Oberhoff C et al: Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer. Ann Oncol 16: 64-69, 2005.
16. Stuart N, Bishop L, Johnson SRD et al: Vinorelbine and capecitabine for advanced breast cancer. A phase II study showing good activity and potential for further development. Proc Am Soc Clin Oncol (Abstr 183), 2003.
17. Albain KS, Nag S, Calderillo-Ruiz et al: Global phase HI study of gemcitabine plus paclitaxel (GT) vs paclitaxel (T) as front line therapy for metastatic breast cancer (MBC): first report of overall survival. Proc Am Soc Clin Oncol (Abstr 510), 2005.
18. Gradishar WJ, Meza LA, Amin B et al: Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study. J Clin Oncol 22: 2321-2327, 2004.
19. Reyes S, Torrecillas L, Acosta A et al: Capecitabine and taxanes: combination versus sequential therapy in anthracycline-pretreated metastatic breast cancer: finding from the Mexican oncology study group phase III. Eur J Cancer 1: S136 (Abstr 447), 2003.
20. Freyer G, Delozier T, Lichinster M et al: Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 21: 35-40, 2003.
21. Gligorov J, Beerblock K, Selle F et al: Capecitabine and oral vinorelbine in metastatic breast cancer patients: preliminary experience. Proc Am Soc Clin Oncol (Abstr 351), 2003.